Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

7 Jan 2021

Abstract excerpt

High-risk neuroblastoma (NB) is responsible for a disproportionate number of childhood deaths due to cancer. One indicator of high-risk NB is amplification of the neural MYC (MYCN) oncogene, which is currently therapeutically intractable. Identification of anaplastic lymphoma kinase (ALK) as an NB oncogene raised the possibility of using ALK tyrosine kinase inhibitors (TKIs) in treatment of patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer therapeutics and mechanisms
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33411331
DOI: 10.15252/embj.2020105784

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutationPMID 33411331Read ↗

Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangementsSemantic proximity Read ↗

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.Semantic proximity Read ↗

ALK in Neuroblastoma: Biological and Therapeutic ImplicationsSemantic proximity Read ↗

Targeting anaplastic lymphoma kinase in neuroblastomaSemantic proximity Read ↗

ALK pERKs up MYCN in neuroblastoma.Semantic proximity Read ↗

Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived CancerSemantic proximity Read ↗

Targeted Therapy for Neuroblastoma: ALK InhibitorsSemantic proximity Read ↗

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted TreatmentSemantic proximity Read ↗

ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.Semantic proximity Read ↗

The ALK receptor in sympathetic neuron development and neuroblastoma.Semantic proximity Read ↗

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastomaSemantic proximity Read ↗

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.